TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies...

TW's Take: the promise of TFF's technology continues to be advanced. Research shows the Company’s Thin Film Freezing can reformulate broad range of monoclonal...

TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

TW's Take: much needed capital provides a runway through data in Q4. Insider participation in the financing is a positive and it's now time...

TFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening of an Expanded...

TW's Take: yet another sign that the product works and is uniquely improved over the currently approved version of the drug. Voriconazole Inhalation Powder...

TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine

TW's Take: more confirmation of the potential of thin-film-freezing in this excellent endorsement from NIH. We continue to await data from their lead programs...

TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to...

TW's Take: nice to see that the technology continues to impress enough to sign a CRADA but we await the real news of phase...

TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under...

TW's Take: nice to see that this program continues to advance. TFF has been quiet for a while. Expect to see some more news...

TFF Pharmaceuticals Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer

TW's Take: Looking forward to getting updates on their in-house programs. The stock is very inexpensive but investors need to gain some degree of...

TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer

TW's Take: this is a great step, bringing in house the expertise needed to take products through clinical development and commercialization or partnering. FORT WORTH,...

TFF Pharmaceuticals Announces Leadership Transition

TW's Take: this has been a long time coming with the company's outstanding technology never seeming to get out of the starting gate under...

TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants

TW's Take: removing the financing overhang is great news for investors. The company now has a runway to reach key milestones over the next...

TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of...

TW's Take: another early stage partnership that positions TFF well for next-gen vaccines but does little to overcome the concerns around the company's finances....

TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus Inhaled Powder Clinical...

TW's Take: tough to understate just how disappointing these delays are to investors. Management's guidance on the timing of these programs has been flat-out...

TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use...

TW's Take: positive results that are meaningful to the big picture here but will be ignored in light of the continual delays in this...

TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at...

TW's Take: the body of data supporting Thin Film Freezing continues to expand. We need to see some partnerships for the share price to...

TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder (TFF VORI) at...

TW's Take: this is excellent news as it confirms the benefits of thin film freezing in Voriconazole, ie reduced toxicity, better efficacy. As VORI...

Pendulum Swings

Market movements are similar to the arc of a pendulum. They swing way past fair value in one direction only to see the inertia...

Taking the Long View on TFF

This week my group had a Zoom call with TFF Pharma (TFFP). Over the past year TFF has become a very polarizing stock. There...

TFF Pharmaceuticals Expands R&D Operations with New Austin Facility

TW's Take: this quote, "as many of our partnered programs move to clinical evaluation", is what the investment community is looking for. When TFF...

Going Downhill

This past weekend I spent mountain biking in Downieville. Our group gets shuttled up to the top of the mountain and then careen down...

High Degree of Confidence

This week I'm writing my newsletter on Thursday as I'm heading out to California this afternoon. The upcoming weekend will be spent in Downieville,...

June Gloom

In San Diego, this time of year the mornings can bring coastal fog. Referred to as "June Gloom", it usually lingers until late in...

CEO Knows Best

The saying about insider stock transactions goes like this, "there are many reasons for insiders to sell but only one reason for them to...

It’s Still The Early Innings

Two weeks ago this newsletter was titled, "Don't Fight The Fed". That week I discussed why the market was headed lower. The bottom line...

TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

TW's Take: continued visible progress on their internal programs, and behind the scenes on partnerships, positions TFF for a number of major catalysts over...

TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Technology...

TW's Take: the versatility of thin-film-freezing is set to open up a broad swath of products that will benefit from this technology. Continue to...

The Rolling Correction Gathers Steam…

Thus endeth the worst month for the stock market since March of 2020. Friday's meltdown took the S&P to -9% for the month. It's...

It’s A Process

This past week in Charlottesville, The Boar's Head Women's Open took place. This is an annual tennis tournament featuring 32 professional tennis players, most...

TFF Announces Data from Phase 1 Study of Niclosamide

TW's Take: this is excellent data and positions Niclosamide well for potentially being a very useful covid-19 therapeutic. We are highly optimistic that UNION...

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business...

TW's Take: lots going on with TFF. While the street awaits partnerships, their internal programs advance on all fronts and they are hiring to...

TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to...

TW's Take: we are finally(!) getting a TFF covid vaccine into testing. This is a positive sign as USAMRIID must like what they have...

Groundhog Day

Another week in the market, another leg down. Some pundits are saying we are now entering a bear market. Those of us who invest...

This Trend is NOT Your Friend

Volodymyr Zelenskyy is a hero. Contrary to what I thought would happen last week, Ukraine is putting up a valiant battle, holding off the...

TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement

TW's Take: a solid endorsement of TFF's technology by one of largest manufacturers in the business. Catalent, an $18B company, will be using their...

TFFP: More Thoughts Regarding NICLOSAMIDE

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

Putin It In Perspective

By the time you read this newsletter, there's a good chance that the Ukraine will be begging for a ceasefire and, basically, surrendering to...

TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of...

TW's Take: this is a very important PR for TFF. Not only does this demonstrate that TFF's version of niclosamide could be the best...

Metamorphosis

What a week in the markets, right? The past five days saw the biggest ever one day loss by a single company, followed shortly...

This Week’s Billboard Headline…Glenn Mattes Stars As Rocky Balboa!

When we had kids I was super excited to watch classic movies with them once they were old enough. Top on my list was...

TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to...

TW's Take: with data from this program expected sometime in March, Niclosamide could be a very big value driver for TFF. UNION would have...

Welcome to 2022?

So much for thinking 2022 was going to be an improvement over last year. Last Sunday I tested positive for covid then, on Monday,...

Happy New Year!!!

Investing in micro-cap stocks with a 3-5 year time horizon, which is my expectation for a holding period every time I enter a position,...

TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in...

TW's Take: we continue to believe, and the data supports this, that TFF's internal programs are worth more than the current market cap of...

Who Believes? Santa Rally Coming…

Yesterday it was 70 degrees in Charlottesville. While playing platform tennis in a t-shirt and shorts, the comment was made that it seems unlikely...

TFF Pharmaceuticals Hosting Science Day on December 13, 2021

TW's Take: the performance of Thin Film Freezing continues to excel in all aspects. This science day should help explain the multiple competitive advantages...

Bottom Picking

My constant refrain for most of 2021 has been that I don't like the market but love the stocks in my portfolio. I can...

Is OMICRON Potentially Positive For TFF Pharma?

The latest strain of Covid-19, officially called B.1.1.529 but dubbed Omicron, struck fear in the markets last week. Omicron appears to have 30 different...

Turkey Shoot…December Preview

Well, that didn't last long, did it? On Tuesday and Wednesday we saw what looked like a great reversal for biotech. The XBI opened...

The Worst Bull Market Ever

Similar to how the richest billionaires are getting a disproportionate amount of the wealth in the US, the companies they founded are becoming an...

TFF Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

TW's Take: a great update. Feels like TFF is on the precipice of big things. In a year, we will have forgotten all about...

TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder...

TW's Take: Voriconazole is a great example of a drug whose efficacy and addressable market can be greatly improved by Thin Film Freezing. Looking...

TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical Trials for Inhaled...

TW's Take: long-awaited news could lead to a rapid trial and UNION picking up the option on this drug sometime in Q1. This drug...

Saturday Morning Musings

In a slow week for news from our universe of companies, the biggest news was from TFF Pharma (TFFP) which announced pre-clinical success of...

Why TFF’s Hamster Data Is Bigger Than Investors Think

As the Delta variant of Covid-19 has demonstrated quite clearly, despite the success of the vaccine programs, the virus is here to stay. Getting...

TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation...

TW's Take: very bullish news. This is the first dry powder (inhalable) treatment to show positive results. It also validates the mAb platform as...

Cash is King

After several weeks of lower stock prices, the market this past week decided that the looming bankruptcy of the world's largest real estate debt...

TFF Pharmaceuticals Announces Promising Topline Results from Phase 1 Clinical Trial of Inhaled Tacrolimus...

TW's Take: very positive data. Inhaled tacrolimus is showing itself to be everything TFF claims for their products; equally efficacy at lower doses, resulting...

When The Tide Goes Out, You See Who’s Swimming Naked…

The markets had another downward-trending week since the last newsletter. However, the overall tone of the market felt better from a micro-cap investing standpoint...

A September To Remember?

I read this week where someone said, "the short story is always sexier." There's certainly a lot of truth in that. Here in September...

Summer Stocks

The markets seem to be quieting down as summer heats up and traders are heading to the beach for the last few weeks of...

TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

TW's Take: TFF continues to have lots of balls in the air. The second half should be exciting with many catalysts coming together. AUSTIN, Texas, Aug....

Are We Having Fun Yet? Bull Ride Continues

The "bull" market continued this past week although it showed signs of tiring. Which is good because the bull ride we've been on resembles...

Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization...

TW's Take: very exciting news as TFF's internal program (with partner Augmenta) appears to be effective against all strains of Covid-19. Expect to see...

TFF Pharmaceuticals Announces Completion of Enrollment and Preliminary Data from its Phase 1 Clinical...

TW's Take: we continue to believe that TAC represents a potential $1B drug and the data continues to be much better than expected or...

Kentucky Bluegrass

In a holiday shortened week, this newsletter comes from Kentucky where the TW household is attending a family wedding. Throw in a side journey...

Let’s Get Ready To Rumble (2nd Half Preview)

To steal a line from Charles Dickens, "It was the best of times. It was the worst of times. Then it was pretty darn...

Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody Candidate AUG-3387 for...

TW's Take: this is potentially a major breakthrough for regions of the world where cold-chain drug distribution doesn't exist. Looking forward to more information...

Put The Hammer Down…Backgammon Lessons

Back in February, on our trip to Miami, I was fortunate to be introduced to a friend of a friend named "Phil". Phil just...

Stock Picking Wins This Week

It was another great week for TW as the pendulum appears to be swinging full speed in our direction. This while the overall market...

TFF Pharmaceuticals Hosting Key Opinion Leader Perspectives on Thin Film Freezing Applications

TW's Take: this call should lay out a compelling thesis for the long-term disruptive case for thin film freezing. We believe this delivery technology...

Oregon Trails

Greetings from Ashland, Oregon where my tour of the west coast is ending in fine fashion. The biking here is outstanding, the meals our...

Resetting Expectations for TFF Pharma

Thin Film Freezing, the drug delivery method being developed by TFF Pharma (TFFP), is an exciting technology that has the potential to change the...

Gas Lines and Inflation…Is This The 80’s?

This past week saw yet another ugly market for micro-caps as the whole investment community seems to be increasingly worried about inflation and interest...

TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

TW's Take: better than expected data leading to TFF increasing the target sales for TAC to over $1B is a positive development, especially as...

The Beatings Will Continue Until Morale Improves…

Okay, I was early. I admit it. But, unless growth stocks never rally again, biotech in particular, I'm 100% convinced that buying at these...

Alpha-Bet Soup

There are times when stock picking isn't the most important part of your investment strategy. When all that matters is being in the right...

The Lows Appear To Be In Place

Earlier this year I was preaching caution. The markets were en fuego and, simply put, this cannot last. While I run pretty fully invested...

How Long Can You Hold A Soccer Ball Under Water?

Last week I wrote about INmune Bio (INMB). In that piece, In Defense of INmune, I discussed the increasing spread between perception of what's...

TFF Pharmaceuticals Awarded Contract under DARPA’s Next-Generation Personalized Protective Biosystems Program for U.S. Warfighters

TW's Take: while the size of the contract is not specified, getting into a DARPA program is a very positive validation of TFF's technology....

A Catalyst Filled Quarter Lies Around The Corner

My wife and I spent Good Friday in the car, driving up to Massachusetts to visit my number one newsletter fan; my mother. It...

2nd Degree of Risk

Investing in micro-caps always involves a high degree of risk. This risk can come in many different forms as well. For example, looking at...

TFF Pharmaceuticals Prices Offering of Common Stock

TW's Take: enough cash to bring in another program, created an internal sterile vaccine line and last until 2024 is a good thing at...

Sitting On My Hands

My Investment Style...It's Not For Everyone But It Works For Me I'm often asked why I don't trade more often. Many of my stocks make...

Technically Speaking

I've always thought that technical analysts were like lawyers; you can always find one who will tell you what you want to hear. That said,...

Recapping TFF’s Shareholder Update Call

With a disruptive platform comes lots of opportunity. I have been hammering on investors for months, saying that TFF Pharma (TFFP) has the opportunity...

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results

TW's Take: the company is executing on all fronts, highlighted by this partnership with the US government which is very validating of the technology....

NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration

TW's Take: yet another shot on goal for TFF. The broad potential of their drug delivery platform is driving companies to work with them...

Feasibility Arrangement for shelf-stable powder form of messenger RNA COVID-19 Vaccine Candidate announced by...

TW's Take: Greenlight Biosciences is well funded and led by a highly-regarded scientist. The potential behind this partnership is significant. TFF is by far...

Blood In The Water

Good Morning Vietnam! Okay, I'll confess to exaggerating a little; I neither live nor work in a war zone. It only just felt like...

TFF Pharmaceuticals Provides Update on Clinical Development Programs

TW's Take: both internal programs continue to exceed expectations. If there was ever a doubt that TFF's product works, this should definitively put that...

Miami Advice

The past year has been all about the pandemic. First it was about selling everything. Like every other market meltdown, it was viewed as...

TFF Pharmaceuticals Announces Positive Preclinical Results with Two Biodefense Countermeasures for the United States...

TW's Take: These are very important data as TFF continues to prove the viability of the thin film freezing technology in vaccine development. The...

Heard On The Street

When I started in this business in the 1980s, "Heard on the Street" was a market moving column in the Wall Street Journal. R....

Riding the Waves

This is without a doubt the most amazing market of my career. It's obviously a bull market as indexes continue to head higher. But,...

The GameStop Impact…January In Review

What a crazy way to end a wild month, huh? As GameStop (GME) continued to rally in the face of shorts, Robin Hood required...

When Will The Music Stop?

When you write a newsletter, being speechless is not a great place to be. However, what I'm seeing in the market right now leaves...

BOOM…Atomera Deal Highlights Another Bull Ride In The Market

Nothing seems to be able to get in the way of this bull market. An insurrection in DC? Yawn. The next administration taking on...

TFF Pharmaceuticals Announces First Dosing of Asthma Patients with Voriconazole Inhalation Powder in a...

TW's Take: success in asthma would greatly increase the Target Addressable Market for Voriconazole as well as speed enrollment of the upcoming pivotal phase...

Climbing The Wall Of Worry…

That certainly was a crazy week. The news from our companies was positive, the news on the CoronaVirus was negative, volatility within our coverage...

The Micro-Cap Rally Continues Full Force

November was truly a month to remember for the markets. The best month in over 40 years for the Russell 2000 saw that index...

The Biden Rally

As most of my readers know, I reserve Saturday mornings for writing my weekly newsletter. This week, however, Saturday morning marks the arrival of...
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.